Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7389
    +0.0016 (+0.22%)
     
  • CRUDE OIL

    83.11
    +1.76 (+2.16%)
     
  • Bitcoin CAD

    95,906.68
    +2,554.50 (+2.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +42.10 (+1.90%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ futures

    18,465.00
    -38.75 (-0.21%)
     
  • VOLATILITY

    13.01
    +0.23 (+1.80%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6843
    +0.0038 (+0.56%)
     

Nektar: 4Q Earnings Snapshot

SAN FRANCISCO (AP) _ Nektar Therapeutics (NKTR) on Thursday reported a loss of $117.2 million in its fourth quarter.

On a per-share basis, the San Francisco-based company said it had a loss of 65 cents.

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.

The biopharmaceutical company posted revenue of $23.5 million in the period, which also beat Street forecasts. Eight analysts surveyed by Zacks expected $19.6 million.

For the year, the company reported that its loss widened to $444.4 million, or $2.49 per share. Revenue was reported as $152.9 million.

ADVERTISEMENT

Nektar shares have increased 32% since the beginning of the year. The stock has increased slightly more than 1% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR